Skip to main content
Equibles
NRXS logo

NRXS · Neuraxis, INC · Metrics

Track NRXS — free

Use NRXS with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research NRXS.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$5.74 +0.05 (+0.88%) At close · Sep 11
Rebalance outlook locked
Going-concern doubt — flagged Aug 11, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Neither future cash generated from operating activities, nor management’s contingency plans to mitigate the risk and extend cash resources through the evaluation period, are considered probable. As a result, substantial doubt is deemed to exist about the Company’s ability to continue as a going concern.”
View the 10-Q filed Aug 11, 2026
Market Cap
$72.08M
Shares
12.56M

NRXS metrics

61 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$5.74
Market cap
$72.08M

Price action

20 metrics
Price change (1W)
-6.3%
Price change (30D)
-9.4%
Price change (3M)
-17.4%
Price change (6M)
-12.2%
Price change (YTD)
+25.3%
Price change (1Y)
+133.2%
Trailing year
Price change (5Y)
—
52-week high
$8.81
52-week low
$2.31
Change from 52-week high
-35.4%
Change from 52-week low
+146.3%
Annualized volatility
73.0%
Annualized volatility (3M)
44.2%
Beta
1.6
RSI (14D)
34.0
Price vs SMA 50
-12.7%
Price vs SMA 200
-5.2%
Avg volume (3M)
82,436
Relative volume
0.6
Average dollar volume
$545,722

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
12.56M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
13.4×
reciprocal yield 7.4%
P / book
10.6
reciprocal yield 9.4%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-10.7%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-11

Profitability

9 metrics
Gross margin
85.6%
Operating margin
-144.5%
Trailing 12 months
Net margin
-144.4%
Gross profit (TTM)
$4.55M
Operating profit (TTM)
−$7.68M
Net income (TTM)
−$7.68M
Trailing 12 months
Diluted EPS (TTM)
$-0.77
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$0.32

Growth

11 metrics
Revenue growth YoY
+115.7%
Year over year
Net income growth YoY
—
Revenue (TTM)
$5.32M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+42.2%
Year over year · more shares
Revenue CAGR (3Y)
+10.0%
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-114.0%
Return on assets
-76.8%
Debt / equity
—
Current ratio
3.0
EBITDA (TTM)
−$7.61M
Free cash flow (TTM)
—
Quick ratio
3.0
Interest coverage
-73.7
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$8.32M
Total assets
$10.00M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$5.62M
Capital expenditures (TTM)
$12,165
R&D (TTM)
$634,458
SG&A (TTM)
—
Stock compensation (TTM)
$1.29M
R&D / revenue
11.9%
Stock compensation / revenue
24.2%

Ownership (13F)

3 metrics
13F filers
32
13F filer change QoQ
+6
Institutional ownership
21.7%

Short interest

3 metrics
Short interest
2.0%
Latest settlement · 3.7 days to cover
Days to cover
3.7d
Short-squeeze score
45 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1933567 CUSIP 64134X201 13F (30d) 19 filings 19 filers Visit website Investor relations